Undergraduate |
Princeton University |
|
1965 |
A.B. |
Medical School |
Johns Hopkins University School of Medicine |
|
1969 |
M.D. |
Residency |
Johns Hopkins Hospital |
|
1971 |
Resident, Internal Medicine |
Fellowship |
University of Alabama at Birmingham |
|
1975 |
Fellow in Cardiology |
|
Internal Medicine, American Board of Internal Medicine |
1974 |
Cardiovascular Disease, American Board of Internal Medicine |
1975 |
|
Organization Name |
Position Held |
Org Link |
Fellow, American College of Cardiology |
Governor for State of Alabama, 1985-88 |
|
Fellow, American College of Physicians |
|
|
Fellow, Council on Clinical Cardiology of the American Heart Association |
Council Representative, 1986-89; Committee on Intensive Cardiac Care 1990-93 |
|
|
Publication |
PUBMEDID |
1. Rogers WJ, Canto JG, Lambrew CT, Tiefenbrunn AJ, Kinkaid B, Shoultz DA, Frederick PD, Every N. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the US from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2, and 3. Journal of the American College of Cardiology 2000;36:2056-2063 |
|
6. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, and Zeiher AM for the ODYSSEY OUTCOMES Committees and Investigators (including Rogers WJ). Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018; 379:2097-107. |
|
5. Canto JG, Rogers WJ, Goldberg RJ, Peterson ED, Wenger NK, Vaccarino V, Kiefe CI, Frederick PD, Sopko G, Zheng ZJ, NRMI Investigators. Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality. JAMA 2012;307:813-822. |
|
4. Mega JL, Hochholzer W, Frelinger AL 3rd, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011;306:2221-2228. |
|
3. The BARI 2D Study Group (including Rogers WJ). A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15. |
|
2. Rogers WJ, Frederick PD, Stoehr E, Canto JG, Ornato JP, Gibson CM, Pollack CV Jr, Gore JM, Chandra-Strobos N, Peterson ED, French WJ. Trends in presenting characteristics and hospital mortality among patients with ST elevation and non-ST elevation myocardial infarction in the National Registry of Myocardial Infarction from 1990 to 2006. Am Heart J 2008; 156:1026-34. |
|
|
|